W. Coley, The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc R Soc Med, vol.3, pp.1-48, 1910.

G. Mathé, L. Schwarzenberg, O. Halle-pannenko, and M. Simmler, DISCUSSION PAPER: EXPERIMENTAL AND CLINICAL IMMUNOPHARMACOLOGY DATA APPLICABLE TO CANCER IMMUNOTHERAPY, Annals of the New York Academy of Sciences, vol.277, issue.1 International, pp.467-84, 1976.
DOI : 10.1111/j.1749-6632.1976.tb41721.x

A. Alexandroff, S. Nicholson, P. Patel, and A. Jackson, Recent advances in bacillus Calmette???Guerin immunotherapy in bladder cancer, Immunotherapy, vol.2, issue.4, pp.551-60, 2010.
DOI : 10.2217/imt.10.32

R. Schreiber, L. Old, and M. Smyth, Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.144, issue.5, pp.1565-70, 2011.
DOI : 10.1016/j.cell.2011.02.013

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

J. Kirkwood, M. Strawderman, M. Ernstoff, T. Smith, E. Borden et al., Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684., Journal of Clinical Oncology, vol.14, issue.1, pp.7-17, 1996.
DOI : 10.1200/JCO.1996.14.1.7

S. Rosenberg, J. Yang, D. White, and S. Steinberg, Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2, Annals of Surgery, vol.228, issue.3, pp.307-326, 1998.
DOI : 10.1097/00000658-199809000-00004

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466

D. Chen and I. Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity, vol.39, issue.1, pp.1-10, 2013.
DOI : 10.1016/j.immuni.2013.07.012

C. Robert, J. Soria, and A. Eggermont, Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies, European Journal of Cancer, vol.49, issue.14, pp.2968-71, 2013.
DOI : 10.1016/j.ejca.2013.07.001

J. Couzin-frankel, Breakthrough of the year 2013, Cancer immunotherapy. Science, vol.342, issue.6165, pp.1432-1435, 2013.

D. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-64, 2012.
DOI : 10.1038/nrc3239

Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proceedings of the National Academy of Sciences, vol.264, issue.5161, pp.12293-12300, 2002.
DOI : 10.1126/science.7513904

O. Talay, C. Shen, L. Chen, and J. Chen, B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation, Proceedings of the National Academy of Sciences, vol.180, issue.1, pp.2741-2747, 2009.
DOI : 10.1084/jem.20022235

M. Keir, M. Butte, G. Freeman, and A. Sharpe, PD-1 and Its Ligands in Tolerance and Immunity, Annual Review of Immunology, vol.26, issue.1, pp.677-704, 2008.
DOI : 10.1146/annurev.immunol.26.021607.090331

A. Lesokhin, M. Callahan, M. Postow, and J. Wolchok, On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation, Science Translational Medicine, vol.12, issue.19, pp.280-281, 2015.
DOI : 10.1186/1479-5876-8-71

T. Azuma, S. Yao, G. Zhu, A. Flies, S. Flies et al., B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells, Blood, vol.111, issue.7, pp.3635-3678, 2008.
DOI : 10.1182/blood-2007-11-123141

W. Zou and L. Chen, Inhibitory B7-family molecules in the tumour microenvironment, Nature Reviews Immunology, vol.106, issue.6, pp.467-77, 2008.
DOI : 10.1038/nri2326

H. Dong, S. Strome, D. Salomao, H. Tamura, F. Hirano et al., Tumor-associated B7- H1 promotes T-cell apoptosis: a potential mechanism of immune evasion, Nat Med, vol.8, issue.8, pp.793-800, 2002.

S. Topalian, C. Drake, and D. Pardoll, Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell, vol.27, issue.4, pp.450-61, 2015.
DOI : 10.1016/j.ccell.2015.03.001

C. Crane, A. Panner, J. Murray, S. Wilson, H. Xu et al., PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer, Oncogene, vol.104, issue.2, pp.306-318, 2009.
DOI : 10.1038/onc.2008.384

A. Parsa, J. Waldron, A. Panner, C. Crane, I. Parney et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma, Nature Medicine, vol.8, issue.1, pp.84-92, 2007.
DOI : 10.1038/nm1517

J. Taube, R. Anders, G. Young, H. Xu, R. Sharma et al., Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.27, issue.36, pp.127-164, 2012.
DOI : 10.1200/JCO.2009.23.4799

I. Barsoum, C. Smallwood, D. Siemens, and C. Graham, A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells, Cancer Research, vol.74, issue.3, pp.665-74, 2014.
DOI : 10.1158/0008-5472.CAN-13-0992

M. Atefi, E. Avramis, A. Lassen, D. Wong, L. Robert et al., Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma, Clinical Cancer Research, vol.20, issue.13, pp.3446-57, 2014.
DOI : 10.1158/1078-0432.CCR-13-2797

D. Chen, B. Irving, and F. Hodi, Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clinical Cancer Research, vol.18, issue.24, pp.6580-6587, 2012.
DOI : 10.1158/1078-0432.CCR-12-1362

J. Yang, L. Riella, S. Chock, T. Liu, X. Zhao et al., The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo, The Journal of Immunology, vol.187, issue.3, pp.1113-1122, 2011.
DOI : 10.4049/jimmunol.1100056

S. Topalian, C. Drake, and D. Pardoll, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Current Opinion in Immunology, vol.24, issue.2, pp.207-219, 2012.
DOI : 10.1016/j.coi.2011.12.009

S. Topalian, F. Hodi, J. Brahmer, S. Gettinger, D. Smith et al., Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012.
DOI : 10.1056/NEJMoa1200690

C. Robert, G. Long, B. Brady, C. Dutriaux, M. Maio et al., Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015.
DOI : 10.1056/NEJMoa1412082

URL : https://hal.archives-ouvertes.fr/hal-00872683

H. Borghaei, L. Paz-ares, L. Horn, D. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015.
DOI : 10.1056/NEJMoa1507643

J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2015.
DOI : 10.1056/NEJMoa1504627

R. Motzer, B. Escudier, D. Mcdermott, S. George, H. Hammers et al., Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.373, issue.19, pp.1803-1816, 2015.
DOI : 10.1056/NEJMoa1510665

A. El-khoueiry, I. Melero, T. Crocenzi, T. Welling, C. Yau et al., Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040., Journal of Clinical Oncology, vol.33, issue.18_suppl, p.2015
DOI : 10.1200/jco.2015.33.18_suppl.lba101

J. Hamanishi, M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi et al., Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer, J Clin Oncol, vol.32, p.5

S. Antonia, J. Bendell, M. Taylor, E. Calvo, D. Jaeger et al., Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032, J Clin Oncol, vol.33, p.2015

C. Robert, J. Schachter, G. Long, A. Arance, J. Grob et al., Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015.
DOI : 10.1056/NEJMoa1503093

E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian et al., Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015.
DOI : 10.1056/NEJMoa1501824

R. Herbst, P. Baas, D. Kim, E. Felip, J. Pérez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, The Lancet, vol.387, issue.10027, pp.1540-50, 2016.
DOI : 10.1016/S0140-6736(15)01281-7

E. Plimack, J. Bellmunt, S. Gupta, R. Berger, R. Montgomery et al., Pembrolizumab (MK-3475) for advanced urothelial cancer : Updated results and biomarker analysis from KEYNOTE-012, J Clin Oncol, vol.33, p.2015

T. Doi, S. Piha-paul, S. Jalal, H. Mai-dang, S. Yuan et al., MK- 3475) for patients (pts) with advanced esophageal carcinoma : Preliminary results from KEYNOTE-028, J Clin Oncol, vol.33, p.2015

P. Ott, E. Fernandez, M. Hiret, S. Kim, D. Moss et al., MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028, MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028. Eur Cancer Congr 2015 Abstr502, p.2015

D. Le, J. Uram, H. Wang, B. Bartlett, H. Kemberling et al., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, New England Journal of Medicine, vol.372, issue.26, pp.2509-2529, 2015.
DOI : 10.1056/NEJMoa1500596

M. Atkins, R. Kudchakar, M. Sznol, D. Mcdermott, J. Schachter et al., Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma, J Clin Oncol, 2014.

R. Herbst, J. Soria, M. Kowanetz, G. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.9, issue.7528, pp.563-570, 2014.
DOI : 10.1038/nature14011

D. Mcdermott, J. Sosman, M. Sznol, C. Massard, M. Gordon et al., Atezolizumab, an Anti???Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study, Journal of Clinical Oncology, vol.34, issue.8, pp.833-875, 2016.
DOI : 10.1200/JCO.2015.63.7421

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, pp.1837-1883, 2016.
DOI : 10.1016/S0140-6736(16)00587-0

J. Rosenberg, J. Hoffman-censits, T. Powles, M. Van-der-heijden, A. Balar et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, The Lancet, vol.387, issue.10031, pp.1909-1929, 2016.
DOI : 10.1016/S0140-6736(16)00561-4

T. Powles, J. Eder, G. Fine, F. Braiteh, Y. Loriot et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.45, issue.7528, pp.558-62, 2014.
DOI : 10.1038/nature13904

J. Brahmer, S. Tykodi, L. Chow, W. Hwu, S. Topalian et al., Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012.
DOI : 10.1056/NEJMoa1200694

R. Hassan, A. Thomas, M. Patel, J. Nemunaitis, J. Bennouna et al., Safety and clinical activity of avelumab (MSB001078C), an anti-PD-L1 antibody, in patients with advanced

J. Gulley, D. Spigel, K. Kelly, J. Chandler, A. Rajan et al., Avelumab (MSB001078C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy, J Clin Oncol, vol.33, p.2015

M. L. Disis, M. Patel, S. Pant, H. E. Lockhart, A. C. Kelly et al., Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity, J Clin Oncol, vol.33, p.2015

N. Rizvi, J. Brahmer, S. Ou, N. Segal, S. Khleif et al., Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015

N. Segal, S. Ou, A. Balmanoukian, M. Fury, E. Massarelli et al., Safety and efficacy od MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort, J Clin Oncol, vol.33, p.2015

C. Massard, M. Gordon, S. Sharma, S. Rafii, Z. Wainberg et al., Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer, J Clin Oncol, vol.34, p.2016

E. Alley, L. Molife, A. Santoro, K. Beckey, S. Yuan et al., Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028, Cancer Research, vol.75, issue.15 Supplement, pp.103-103, 2015.
DOI : 10.1158/1538-7445.AM2015-CT103

A. Varga, S. Piha-paul, P. Ott, J. Mehnert, D. Berton-rigaud et al., Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 Study, J Clin Oncol J Clin Oncol, vol.33, 2015.

T. Seiwert, R. Haddad, S. Gupta, R. Mehra, M. Tahara et al., Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort., Journal of Clinical Oncology, vol.33, issue.18_suppl, p.2015
DOI : 10.1200/jco.2015.33.18_suppl.lba6008

P. Ott, S. Piha-paul, P. Munster, M. Pishvaian, E. Van-brummelen et al., MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer

Y. Bang, H. Chung, V. Shankaran, R. Geva, D. Catenacci et al., Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 mono, J Clin Oncol, vol.33, p.2015

A. Spira, K. Park, J. Mazières, J. Vansteenkiste, A. Rittmeyer et al., Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR), J Clin Oncol, vol.33, p.2015

L. Emens, F. Braiteh, P. Cassier, J. Delord, J. Eder et al., Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC), Cancer Research, vol.75, issue.15 Supplement, pp.2859-2859, 2015.
DOI : 10.1158/1538-7445.AM2015-2859

M. Sznol and L. Chen, Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer, Clinical Cancer Research, vol.19, issue.5, pp.1021-1055, 2013.
DOI : 10.1158/1078-0432.CCR-12-2063

S. Gettinger, L. Horn, L. Gandhi, D. Spigel, S. Antonia et al., Overall Survival and Long-Term Safety of Nivolumab (Anti???Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.33, issue.18, pp.2004-2016, 2015.
DOI : 10.1200/JCO.2014.58.3708

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

B. Escudier, R. Motzer, P. Sharma, J. Wagstaff, E. Plimack et al., Treatment beyond progression with nivolumab (nivo) in patients with avdanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study, J Clin Oncol, vol.34, p.2016

S. Champiat, O. Lambotte, E. Barreau, R. Belkhir, A. Berdelou et al., Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper, Annals of Oncology, vol.27, issue.4, pp.559-74, 2016.
DOI : 10.1093/annonc/mdv623

J. Naidoo, D. Page, B. Li, L. Connell, K. Schindler et al., Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann Oncol, vol.26, issue.12, pp.2375-91, 2015.

B. Teply and E. Lipson, Identification and management of toxicities from immune checkpointblocking drugs, Oncology, vol.28, pp.30-38, 2014.

M. Teng, S. Ngiow, A. Ribas, and M. Smyth, Classifying Cancers Based on T-cell Infiltration and PD-L1, Cancer Research, vol.75, issue.11, pp.2139-2184, 2015.
DOI : 10.1158/0008-5472.CAN-15-0255

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452411

S. Aspeslagh, S. Postel-vinay, S. Rusakiewicz, J. Soria, L. Zitvogel et al., Rationale for anti-OX40 cancer immunotherapy, European Journal of Cancer, vol.52, pp.50-66, 2016.
DOI : 10.1016/j.ejca.2015.08.021

S. Woo, M. Turnis, M. Goldberg, J. Bankoti, M. Selby et al., Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape, Cancer Research, vol.72, issue.4, pp.917-944, 2012.
DOI : 10.1158/0008-5472.CAN-11-1620

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288154

H. Soliman, M. Mediavilla-varela, and A. S. , Indoleamine 2,3-Dioxygenase, The Cancer Journal, vol.16, issue.4, pp.354-363, 2010.
DOI : 10.1097/PPO.0b013e3181eb3343

M. Hellmann, C. Friedman, and J. Wolchok, Chapter Six -Combinatorial Cancer Immunotherapies Advances in Immunology, Tumor Immunology, vol.2016, issue.130, pp.251-77
DOI : 10.1016/bs.ai.2015.12.005

J. Larkin, V. Chiarion-sileni, R. Gonzalez, J. Grob, C. Cowey et al., Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015.
DOI : 10.1056/NEJMoa1504030

URL : http://www.zora.uzh.ch/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf

J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus et al., Phase I Study of Single-Agent Anti???Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates, Journal of Clinical Oncology, vol.28, issue.19, pp.3167-75, 2010.
DOI : 10.1200/JCO.2009.26.7609

F. Hodi, M. Sznol, H. Kluger, D. Mcdermott, R. Carvajal et al., Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial, J Clin Oncol, 2014.

N. Rizvi, J. Mazières, D. Planchard, T. Stinchcombe, G. Dy et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, The Lancet Oncology, vol.16, issue.3, pp.257-65, 2015.
DOI : 10.1016/S1470-2045(15)70054-9

M. Dolled-filhart, C. Roach, G. Toland, J. Musser, G. Lubiniecki et al., Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015

R. Kefford, A. Ribas, O. Hamid, C. Robert, A. Daud et al., Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475, J Clin Oncol, 2014.

L. Carbognin, S. Pilotto, M. Milella, V. Vaccaro, M. Brunelli et al., Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers, PLOS ONE, vol.348, issue.6230, p.130142, 2015.
DOI : 10.1371/journal.pone.0130142.s001

J. Taube, A. Klein, J. Brahmer, H. Xu, X. Pan et al., Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy, Clinical Cancer Research, vol.20, issue.19, pp.5064-74, 2014.
DOI : 10.1158/1078-0432.CCR-13-3271

J. Weber, D. Angelo, S. Minor, D. Hodi, F. Gutzmer et al., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015.
DOI : 10.1016/S1470-2045(15)70076-8

R. Motzer, B. Rini, D. Mcdermott, B. Redman, T. Kuzel et al., Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial, Journal of Clinical Oncology, vol.33, issue.13, pp.1430-1437, 2015.
DOI : 10.1200/JCO.2014.59.0703

T. Choueiri, M. Fishman, B. Escudier, D. Mcdermott, H. Kluger et al., Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes, J Clin Oncol, vol.33, p.2015

I. Puzanov, R. Dummer, J. Schachter, A. Pavlick, R. Gonzalez et al., Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL) Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001, J Clin Oncol J Clin Oncol, vol.33, issue.33, p.2015, 2015.

J. Soria, O. Flotten, L. Horn, E. Felip, L. Gandhi et al., Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

J. Vansteenkiste, L. Fehrenbacher, A. Spira, J. Mazieres, K. Park et al., 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR), European Journal of Cancer, vol.51, 2015.
DOI : 10.1016/S0959-8049(15)30072-1

L. Horn, D. Spigel, S. Gettinger, S. Antonia, M. Gordon et al., Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study, J Clin Oncol, vol.33, p.2015

D. Petrylak, T. Powles, J. Bellmunt, F. Braiteh, Y. Loriot et al., A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC), J Clin Oncol, vol.33, p.2015

M. Disis, M. Patel, S. Pant, E. Hamilton, A. Lockhart et al., Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: A phase Ib trial reporting safety and clinical activity. Eur Cancer Congr, 2015.

B. Higgs, P. Robbins, A. Blake-haskins, W. Zhu, C. Morehouse et al., High tumoral IFN ? mRNA, PD-L1 protein, and combined IFN? mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1)
DOI : 10.1016/s0959-8049(16)31937-2

T. Seiwert, B. Burtness, J. Weiss, I. Gluck, J. Eder et al., A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV?associated head and neck (H/N) cancer, J Clin Oncol, 2014.

C. Hsu, S. Lee, S. Ejadi, C. Even, R. Cohen et al., Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study. Eur Cancer Congr, 2015.

J. Mclaughlin, K. Schalper, D. Carvajal-hausdorf, V. Pelekanou, V. Velcheti et al., Abstract 1310: Programmed death ligand-1 (PD-L1) heterogeneity in non-small cell lung cancer (NSCLC), Cancer Research, vol.75, issue.15 Supplement, pp.1310-1310, 2015.
DOI : 10.1158/1538-7445.AM2015-1310

M. Ratcliffe, A. Sharpe, A. Midha, C. Barker, P. Scorer et al., Abstract LB-094: A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative:, Am Assoc Cancer Res Congr 2016 Abstr LB094
DOI : 10.1158/1538-7445.AM2016-LB-094

K. Mahoney, H. Sun, X. Liao, P. Hua, M. Callea et al., PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells, Cancer Immunology Research, vol.3, issue.12, pp.1308-1323, 2015.
DOI : 10.1158/2326-6066.CIR-15-0116

S. Patel and R. Kurzrock, PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Molecular Cancer Therapeutics, vol.14, issue.4, pp.847-56, 2015.
DOI : 10.1158/1535-7163.MCT-14-0983

K. Kerr, M. Tsao, A. Nicholson, Y. Yatabe, I. Wistuba et al., Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?, Journal of Thoracic Oncology, vol.10, issue.7, pp.985-994, 2015.
DOI : 10.1097/JTO.0000000000000526

B. Sheffield, Predictive biomarker testing for programmed death 1 inhibition in non-small cell lung cancer. 16th World Conf Lung Cancer, 2015.

J. Madore, R. Vilain, A. Menzies, H. Kakavand, J. Wilmott et al., PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials, Pigment Cell & Melanoma Research, vol.369, issue.3, pp.245-53, 2015.
DOI : 10.1111/pcmr.12340

D. Spigel, J. Chaft, S. Gettinger, B. Chao, L. Dirix et al., Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with nonsmall cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015

J. Adam, D. Planchard, A. Marabelle, J. Soria, J. Scoazec et al., ??valuation de l???expression de PD-L1 en immunohistochimie??: un biomarqueur ??mergent dans les carcinomes pulmonaires non ?? petites cellules, Annales de Pathologie, vol.36, issue.1, pp.94-102, 2016.
DOI : 10.1016/j.annpat.2015.11.004

L. Bracci, G. Schiavoni, A. Sistigu, and F. Belardelli, Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer, Cell Death and Differentiation, vol.118, issue.1, pp.15-25, 2014.
DOI : 10.1038/cdd.2013.67

S. Ngiow, G. Mcarthur, and M. Smyth, Radiotherapy Complements Immune Checkpoint Blockade, Cancer Cell, vol.27, issue.4, pp.437-445, 2015.
DOI : 10.1016/j.ccell.2015.03.015

URL : http://dx.doi.org/10.1016/j.ccell.2015.03.015

X. Jiang, J. Zhou, A. Giobbie-hurder, J. Wargo, and F. Hodi, The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition, Clinical Cancer Research, vol.19, issue.3, pp.598-609, 2013.
DOI : 10.1158/1078-0432.CCR-12-2731

J. Gainor, L. Sequist, T. Shaw, A. Azzoli, C. Piotrowska et al., Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALKrearranged non-small cell lung cancer (NSCLC), J Clin Oncol, vol.33, p.2015

M. Ilie, E. Long-mira, C. Bence, C. Butori, S. Lassalle et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.27, issue.1, pp.147-53, 2016.
DOI : 10.1093/annonc/mdv489

S. Kitazono, Y. Fujiwara, K. Tsuta, H. Utsumi, S. Kanda et al., Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non???Small-Cell Lung Cancer, Clinical Lung Cancer, vol.16, issue.5, pp.385-90, 2015.
DOI : 10.1016/j.cllc.2015.03.008

R. Thompson, S. Kuntz, B. Leibovich, H. Dong, C. Lohse et al., Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up, Cancer Research, vol.66, issue.7, pp.3381-3386, 2006.
DOI : 10.1158/0008-5472.CAN-05-4303

R. Thompson, M. Gillett, J. Cheville, C. Lohse, H. Dong et al., Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma, Cancer, vol.20, issue.10, pp.2084-91, 2005.
DOI : 10.1002/cncr.21470

M. Kowanetz, H. Koeppen, and M. Boe, Spatiotemporal effects on programmed death ligand 1 (PD- L1) expression and immunophenotype of non-small cell lung cancer (NSCLC). 16th World Conf Lung Cancer, p.3, 2015.

*. Tumeh, . Pc, *. M. Rosenblum, N. Handley, K. Tsai et al., Abstract 2857: Metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma, Cancer Research, vol.75, issue.15 Supplement, pp.2857-2857, 2015.
DOI : 10.1158/1538-7445.AM2015-2857

A. Wang, H. Wang, Y. Liu, M. Zhao, H. Zhang et al., The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis, European Journal of Surgical Oncology (EJSO), vol.41, issue.4, pp.450-456, 2015.
DOI : 10.1016/j.ejso.2015.01.020

M. Rebelatto, Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients, J Clin Oncol, vol.33, 2015.

P. Mitchell, C. Murone, and K. Asadi, PD-L1 expression in NSCLC: analysis of a large early stage cohort; and concordance of expression in primary, nodes and metastasis. 16th World Conf Lung Cancer, 2015.

Z. Pan, F. Ye, X. Wu, H. An, and J. Wu, Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis, J Thorac Dis, vol.7, issue.3, pp.462-70, 2015.

B. Howitt, L. Sholl, L. Ritterhouse, J. Watkins, S. Rodig et al., Association of POLEmutated and MSI endometrial cancers with an elevated number of tumor-infiltrating and peritumoral lymphocytes and higher expression of PD-L1, J Clin Oncol, vol.33, p.2015

D. Incecco, A. Andreozzi, M. Ludovini, V. Rossi, E. Capodanno et al., PD-1 and PD- L1 expression in molecularly selected non-small-cell lung cancer patients, Br J Cancer, 2015.

R. Hino, K. Kabashima, Y. Kato, H. Yagi, M. Nakamura et al., Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma, Cancer, vol.17, issue.7 pt 2, pp.1757-66, 2010.
DOI : 10.1002/cncr.24899

X. Meng, Z. Huang, F. Teng, L. Xing, and Y. J. , Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy, Cancer Treatment Reviews, vol.41, issue.10, pp.868-76, 2015.
DOI : 10.1016/j.ctrv.2015.11.001

P. Tumeh, C. Harview, J. Yearley, I. Shintaku, E. Taylor et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, vol.15, issue.7528, pp.568-71, 2014.
DOI : 10.1038/nature13954

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418

J. Yearley, C. Gibson, and N. Yu, 18LBA PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer, Eur Cancer Congr 2015 Abstr 18LBA
DOI : 10.1016/S0959-8049(16)31940-2

X. Frigola, B. Inman, C. Lohse, C. Krco, J. Cheville et al., Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma, Clinical Cancer Research, vol.17, issue.7, pp.1915-1938, 2011.
DOI : 10.1158/1078-0432.CCR-10-0250

R. S. Dronca, S. Markovic, K. L. Mcwilliams, R. R. Block, M. S. et al., Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM), J Clin Oncol, vol.33, p.2015

A. Ribas, C. Robert, F. Hodi, J. Wolchok, A. Joshua et al., Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature, J Clin Oncol, vol.33, p.2015

T. Seiwert, B. Burtness, J. Weiss, J. Eder, J. Yearley et al., Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients, J Clin Oncol, vol.33, p.2015

N. Rizvi, M. Hellmann, A. Snyder, P. Kvistborg, V. Makarov et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.105, issue.51, pp.124-132, 2015.
DOI : 10.1073/pnas.0810114105

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993154

S. Champiat, C. Ferté, S. Lebel-binay, A. Eggermont, and J. Soria, Exomics and immunogenics, OncoImmunology, vol.127, issue.1, p.27817, 2014.
DOI : 10.1126/scitranslmed.3003689

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937193

E. Van-allen, D. Miao, B. Schilling, S. Shukla, C. Blank et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, vol.28, issue.11, pp.207-218, 2015.
DOI : 10.1093/bioinformatics/bts196

M. Buyse, D. Sargent, A. Grothey, A. Matheson, and A. De-gramont, Biomarkers and surrogate end points???the challenge of statistical validation, Nature Reviews Clinical Oncology, vol.3, issue.6, pp.309-326, 2010.
DOI : 10.1038/nrclinonc.2010.43

H. Kohrt, P. Tumeh, D. Benson, N. Bhardwaj, J. Brody et al., Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials, Journal for ImmunoTherapy of Cancer, vol.26, issue.8, p.15, 2016.
DOI : 10.1186/s40425-016-0118-0

URL : https://hal.archives-ouvertes.fr/hal-01440327